Results 191 to 200 of about 5,370,035 (306)

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Cryoglobulinemia Type II: Sustained Remission After B-Cell-Directed Therapy. [PDF]

Am J Case Rep
Suul SG, Kvam AK, Hestdalen ML, Randen U, Midtvedt Ø, Tjønnfjord GE.   +5 more
europepmc   +1 more source

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis [PDF]

Jinchul Kim, Jinhyun Cho, Moon Hee Lee, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim   +5 more
openalex   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

B Cell Receptor's function in virus entry: Anti-SARS-CoV-2 B cell receptors can mediate viral entry in an ACE2-independent mechanism. [PDF]

PLoS Pathog
Larios R, Hossain MB, Brown R, Jeyachandran AV, Abu AE, Zaiss AK, Ramirez CM, Kamata M, Cole S, Wu TT, Dorshkind K, Arumugaswami V, Morizono K.   +12 more
europepmc   +1 more source

Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphoma

, 2010
Michinori Ogura, Toshiki Uchida, Masafumi Taniwaki, Kiyoshi Ando, Takashi Watanabe, Masanobu Kasai, Yosuke Matsumoto, Daisuke Shimizu, Yoshiaki Ogawa, Ken Ohmachi, Hiroki Yokoyama, Kensei Tobinai, the Japanese Bendamustine Lymphoma Study Group   +12 more
openalex   +2 more sources

B cells: B cell back catalogue (remastered) [PDF]

Immunology & Cell Biology, 2008
openaire   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Targetable Vulnerabilities in MYC-Driven B Cell Lymphomas Resistant to BCR Extinction. [PDF]

Hematol Oncol
Brambillasca S, Chantal Parr N, Palmeri A, Andronache A, Arima H, Faga' G, Leuzzi B, Perucho L, Robusto M, Pasi M, Mainoldi F, Fancelli D, Varasi M, Varano G, Mercurio C, Casola S.   +15 more
europepmc   +1 more source